Abstract:
PURPOSE: A GABA(gamma-aminobutyric acid) release inhibitor containing bestrophin 1 channel inhibitor is provided to enable effective and various treatment for GABA-associated disease symptom. CONSTITUTION: A composition for preventing or treating diseases or symptom due to GABA excessive release contains bestrophin 1 channel inhibitor as an active ingredient. The composition suppresses GABA release in the bovine cerebellum. The bestrophin 1 channel inhibitor is an antisense RNA or shRNA of a nucleotide sequence encoding an anion channel blocker and bestrophin 1 channel. The anion channel blocker is niflumic acid, 5-nitro-2(3-phenylpropylamino)-bazoic acid(NPPB) or 4,4'-diisothiocyanatostylbene-2,2'-disulfonic acid(DIDS). The nucleotide sequence encoding the bestrophin 1 channel is a sequence of sequence number 1 or 2. A composition for preventing or treating diseases due to GABA deficiency contains a bestrophin 1 channel activator as an active ingredient. The activator is a peptide TFLLR and Bradykinin.
Abstract:
Methods for treating pains are provided to treat pains including tooth pain and inflammation caused by various stimulators such as temperature, capsaicin and acid by using diacylglycerol and its derivatives, so that the compound is used in functional toothpaste, food and food additives. The pains are treated by activating a capsaicin receptor and transferring calcium into the cells by using diacylglycerol l and its derivatives, wherein the capsaicin receptor contains TRP(transient receptor potential) channel, preferably TRP subtype 1(TRPV1) or by inhibiting function of capsaicin receptor and calcium transfer into the cells by inhibiting the binding of diacyglycerol with 6-iodonorcapsaicin(6-CAP). A composition for treating pains comprises diacylglycerol and its derivatives as effective ingredients.